The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants

Phase 1 Completed 18 enrolled Professor Francois Venter University of Cape Town · collab

NaSequentialOpen-labelTreatment

Summary

This is a pharmacokinetic study investigating the effect of rifampicin on the pharmacokinetics of intracellular tenofovir-diphosphate and plasma tenofovir when coadministered with tenofovir alafenamide fumarate during the maintenance phase of tuberculosis treatment in TB/HIV-1 coinfected participants (EpiTAF)

Timeline

Start: 2019-12-05
Primary completion: 2020-10-30
Completion: 2020-10-30

Publications

Mpofu R, Chandiwana N, Sokhela S, Moorhouse M, Venter F, Anderson PL, Wiesner L, Boffito M, Maartens G, Sinxadi P. The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in HIV-associated Tuberculosis. J Acquir Immune Defic Syndr. 2026 Apr 1;101(4):424-431. doi: 10.1097/QAI.0000000000003810.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rifampicin	Small molecule	600 mg	—
Subject	Rifampicin	Small molecule	750 mg	—
Subject	Tenofovir disoproxil fumarate	Small molecule	300 mg	—
Subject	tenofovir alafenamide	Small molecule	25 mg	—
Background	Efavirenz	Other / unclassified	600 mg	—
Background	Isoniazid	Small molecule	300 mg	—
Background	Lamivudine	Other / unclassified	300 mg	—
Background	emtricitabine	Other / unclassified	200 mg	—

The Effect of Rifampicin on the Pharmacokinetics of Intracellular Tenofovir-diphosphate and Tenofovir When Coadministered With Tenofovir Alafenamide Fumarate During the Maintenance Phase of Tuberculosis Treatment in TB/HIV-1 Coinfected Participants

Summary

Timeline

Publications

Drugs

Indications